Rocket Pharmaceuticals, Inc. Marketable Securities, Unrealized Gain (Loss)
Rocket Pharmaceuticals, Inc. (RCKT) reported Marketable Securities, Unrealized Gain (Loss) of $0 for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2022-08-09
- Rocket Pharmaceuticals, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2017-12-31 was $9.00K.
- Rocket Pharmaceuticals, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2017-09-30 was $47.00K.
- Rocket Pharmaceuticals, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2017-03-31 was -$18.00K, a 263.64% decline year-over-year.
- Rocket Pharmaceuticals, Inc. marketable securities, unrealized gain (loss) for fiscal 2017 was $38.00K.
- Rocket Pharmaceuticals, Inc. marketable securities, unrealized gain (loss) for fiscal 2016 was -$43.00K.
- Rocket Pharmaceuticals, Inc. marketable securities, unrealized gain (loss) for fiscal 2015 was -$11.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2021-06-30 | -$1.00K 10-Q · filed 2022-08-09 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 | ||||
| 2017-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $56.00K derived: sum of 2 quarters · filed 2018-03-07 | $56.00K derived: sum of 3 quarters · filed 2018-03-07 | $38.00K 10-K · filed 2018-03-07 | |
| 2017-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $47.00K derived: sum of 2 quarters · filed 2017-11-08 | $29.00K 10-Q · filed 2017-11-08 | -$27.00K derived: sum of 4 quarters · filed 2018-03-07 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$18.00K 10-Q · filed 2017-08-03 | -$74.00K derived: sum of 3 quarters · filed 2018-03-07 | -$89.00K derived: sum of 4 quarters · filed 2018-03-07 | |
| 2017-03-31 | -$18.00K 10-Q · filed 2017-05-10 | -$74.00K derived: sum of 2 quarters · filed 2018-03-07 | -$89.00K derived: sum of 3 quarters · filed 2018-03-07 | -$72.00K derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-12-31 | -$56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$71.00K derived: sum of 2 quarters · filed 2018-03-07 | -$54.00K derived: sum of 3 quarters · filed 2018-03-07 | -$43.00K 10-K · filed 2018-03-07 | |
| 2016-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.00K derived: sum of 2 quarters · filed 2017-11-08 | $13.00K 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $28.00K 10-Q · filed 2017-08-03 | |||
| 2016-03-31 | $11.00K 10-Q · filed 2017-05-10 | ||||
| 2015-12-31 | -$11.00K 10-K · filed 2017-03-16 | $11.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |